Overview

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone in Study PTC743-NEU-003-FA (NCT04577352) or Study PTC743-NEU-005-FA.
Phase:
Phase 3
Details
Lead Sponsor:
PTC Therapeutics